Navigation Links
AquaFlow™

ProductsAquaFlow™
Company STAAR Surgical Company
Item AquaFlow™
Features 
Description The AquaFlow™ Collagen Glaucoma Drainage Device when used with a non-penetrating deep sclerectomy procedure has been proven to significantly lower intraocular pressure while minimizing both the complications often associated with penetrating procedures and reducing the need for medications. As a result, patient outcomes are predictable and patient follow-up is more easily managed.
Info STAAR Surgical Company
Customer Service: (626) 303-7902
Web site: http://www.staar.com

Related medicine products :

1. ECG-9010 interpretive resting ECG
2. cardiofax Q Mid-level interpretive resting ECG
3. ECG-9320 interpretive resting ECG
4. cardiofax GEM Basic-level interpretive resting ECG
TAG: AquaFlow
The LCS complete knee offers grit-blast textured components for cemented implantation and POROCOAT Porous Coated patellar, femoral and tibial components for cementless fixation.
...ak system includes a cruciate sparing version whic...th both resurfacing and inset patellas. Precision ...atics and fit with tibial articular surface and pa...ocations provide easy intraoperative change of siz...
The Balanced Knee System provides instrumentation designed to achieve proper tissue balancing and alignment with user-friendly instrumentation that provides reproducible results.
Advance Posterior Stabilized Total Knee systems improves patellofemoral kinematics, reduces wear rate potential, increases resistance to posterior tibial dislocation, achieves at least 120o flexion i
Medicine Products:
(Date:8/29/2008)..., Aug. 29 /PRNewswire/ -- In response to recent ne...ic wasting disease (CWD),members of the deer farm..., With hunting season fast approaching, the tragi...r on a Kent County farm understandably has,created...er farmers across,the great state of Michigan. The...
(Date:8/29/2008)...ntific obligation reduced from $250 to $19 million...- Boston Scientific,Corporation (NYSE: BSX ) toda...ll, Texas found two patents of Medtronic, Inc. (NY...uring the prosecution of the patents,before the Un...had previously found that certain Boston Scientifi...
(Date:8/29/2008)... Allsup explains financial implications of ...rs available to people with disabilities. , ... 29, 2008 -- Deciding how to move forward after a ...matter, but it,s important that individuals do as ...ions, according to http://www.allsup.com/ [Allsu...
(Date:8/28/2008)...even after conventional therapy, study found , ...king out on a treadmill improves brain function an...d gone through the usual rehabilitation program, a...hese patients have," said study researcher Dr. And...eurorehabilitation at the University of Zurich in ...
Breaking Medicine News(10 mins):Health News:Deer Farm Industry in Michigan Issues Statement on the Recent Chronic Wasting Disease Case Identified on a Kent County Deer Farm 2Health News:Court Rejects Two Medtronic Patents 2Health News:Court Rejects Two Medtronic Patents 3Health News:Social Security Disability Can Be Key to Financial Future 2Health News:Social Security Disability Can Be Key to Financial Future 3Health News:Social Security Disability Can Be Key to Financial Future 4Health News:Social Security Disability Can Be Key to Financial Future 5Health News:Social Security Disability Can Be Key to Financial Future 6Health News:Treadmill Workouts Help Stroke Survivors 2
...esearchers at the Virginia Bioinformatics Institut...sts to have a better //understanding of the metabo...(azidothymidine, AZT). AZT is used successfully a...Therapy (HAART) to control the level of the human ...
...ess or craw craw is endemic to Bioko Island, Equat.../ in affected individuals thus rendering them list...impacts the economy of this area. The disease is c...ted through the bite of the black fly, Simulium. &...
...sychology showed that men find heavier women more ...who wanted to test their theory linking appetite a... that hungry men preferred heavier women. Dr Vir...artment of Public Health and Dr Martin Tovee from ...
...l conducted by researchers at St. Jude Children's ...of erythropoietin //(EPO) is a very effective trea...op anemia during chemotherapy. EPO is a natural h...moglobin. It reduces the need for red blood cell ...
Other Medicine News:Health News:Computational Model Reveals Working of AZT in Body 2Health News:Onchocerciasis: Presentation And Treatment 2Health News:EPO Effective For Cancer Patients Suffering From Anemia 2
(Date:8/27/2008)... - Patients in the VELCADE, melphalan and predni...efit as well as a 30 percent complete response -, ...ium: The Takeda,Oncology Company today announced t...ndomized, Phase III VISTA(1) trial in this week,s ...e results showed a significant survival,benefit an...
(Date:8/27/2008)... Nationally Recognized Pediatric Heart Center at T...ccess for Community to Complete Range of Care and ...wly Recruited Pediatric Cardiology Team Treats Eve...-USNewswire/ -- The Children,s Hospital at,Montefi...atric heart,transplantation to the Bronx, followin...
(Date:8/26/2008)... Company to present data from landmark SYNT...wire-FirstCall/ -- Boston Scientific,Corporation (...ompany,s major,events and press announcements at t...hich runs from August 30 to September 3 in Munich,... data from the SYNTAX trial,which compares percut...
(Date:8/26/2008)... Study finds most patients can drive safely six...l., Aug. 26 /PRNewswire-USNewswire/ -- Six weeks f...s are so low that they are able to,get back behind...e August,2008 issue of The Journal of Bone and Joi...t emergency brake time response in patients who un...
Breaking Medicine Technology:New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 2New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 3New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 4New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 5New England Journal of Medicine Publishes Phase III Results of VELCADE(R) (Bortezomib) for Injection in Previously Untreated Multiple Myeloma Patients 6Pediatric Heart Transplants at Montefiore Approved by NY State Department of Health 2Pediatric Heart Transplants at Montefiore Approved by NY State Department of Health 3Pediatric Heart Transplants at Montefiore Approved by NY State Department of Health 4Boston Scientific Announces Schedule for European Society of Cardiology Congress 2008 2Boston Scientific Announces Schedule for European Society of Cardiology Congress 2008 3Boston Scientific Announces Schedule for European Society of Cardiology Congress 2008 4Braking After Bunion Surgery 2Braking After Bunion Surgery 3ChanTest Launches New Business to Provide Validated Ion Channel Expressing Cell Lines to the Research Community 6963 1ChanTest Launches New Business to Provide Validated Ion Channel Expressing Cell Lines to the Research Community 6963 2ChanTest Launches New Business to Provide Validated Ion Channel Expressing Cell Lines to the Research Community 6963 3Ben Gurion University of the Negev initiates project to eliminate intestinal worms in Ethiopia 25022 1Ben Gurion University of the Negev initiates project to eliminate intestinal worms in Ethiopia 25022 2Ortho Biotech Announces Nationwide Voluntary Recall of Procrit 28R 29 28Epoetin Alfa 29 Lot Number P114942A 6962 1Ortho Biotech Announces Nationwide Voluntary Recall of Procrit 28R 29 28Epoetin Alfa 29 Lot Number P114942A 6962 2Replidyne Announces Second Quarter 2008 Results From Operations 6959 1Replidyne Announces Second Quarter 2008 Results From Operations 6959 2Replidyne Announces Second Quarter 2008 Results From Operations 6959 3Replidyne Announces Second Quarter 2008 Results From Operations 6959 4Replidyne Announces Second Quarter 2008 Results From Operations 6959 5Replidyne Announces Second Quarter 2008 Results From Operations 6959 6Replidyne Announces Second Quarter 2008 Results From Operations 6959 7
...M, N.C.--(BUSINESS WIRE)--May 8, 2007 - Inspire,Ph... results of a,Phase 2 dose-ranging clinical trial ...tients with seasonal allergic rhinitis. For,the pr...om score,dose-related effects were observed in th...tistical superiority over placebo., Christy L. Sha...
...axin Phase 2 BPD Clinical Data Selected and Presen...Chrysalis Aerosol-Generator Technology,Demonstrate...ay 8, 2007 (PRIME NEWSWIRE) -- Discovery,Laborator...m its,previously completed Phase 2 clinical trial ...on) for the prevention and,treatment of Bronchopul...
Other Medicine Technology:Inspire Announces Positive Results of Phase 2 Trial of Epinastine,Nasal Spray for Seasonal Allergic Rhinitis 2Inspire Announces Positive Results of Phase 2 Trial of Epinastine,Nasal Spray for Seasonal Allergic Rhinitis 3Inspire Announces Positive Results of Phase 2 Trial of Epinastine,Nasal Spray for Seasonal Allergic Rhinitis 4Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric,Academic Societies' Annual Meeting 2Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric,Academic Societies' Annual Meeting 3Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric,Academic Societies' Annual Meeting 4Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric,Academic Societies' Annual Meeting 5Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric,Academic Societies' Annual Meeting 6Discovery Labs Presents Surfaxin and Aerosurf Data At the Pediatric,Academic Societies' Annual Meeting 7